The Province of Saskatchewan is now going to provide coverage for an ALS treatment for those residents who are eligible under the Saskatchewan Drug Plan.

Radicava is an intravenous infusion treatment for people with the progressive nervous system disease that causes loss of muscle control. The province says studies have shown Radicava can slow the progression of ALS, or Lou Gherig’s disease, for people newly diagnosed or in the early stages of the disease.

Radicava costs approximately $123,000 per patient in the first year of treatement and about $120,000 annually after that.